Table of Contents
Chapter 1. Global Oncolytic Virotherapy Market Executive Summary
1.1. Global Oncolytic Virotherapy Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Virus Type
1.3.2. By Application
1.3.3. By End-User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Oncolytic Virotherapy Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Oncolytic Virotherapy Market Dynamics
3.1. Market Drivers
3.1.1. Rising incidence of cancer
3.1.2. Growing approvals for oncolytic therapy for treating rare cancers
3.1.3. Increasing investments for developing new oncolytic virotherapies
3.1.4. Growing focus towards combination therapies
3.2. Market Challenges
3.2.1. Issues related to scaling-up of clinical-grade oncolytic viruses
3.2.2. Requirement for high investments in conducting clinical research
3.3. Market Opportunities
3.3.1. Increasing prevalence of cancer in Asia Pacific
3.3.2. Growing support from governments for advanced cancer care capabilities
3.3.3. Early adoption of innovative therapies in North America
Chapter 4. Global Oncolytic Virotherapy Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Oncolytic Virotherapy Market Size & Forecasts by Virus Type 2022-2032
5.1. Segment Dashboard
5.2. Global Oncolytic Virotherapy Market: Virus Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Genetically Engineered Oncolytic Viruses
5.2.2. Oncolytic Wild-Type Viruses
Chapter 6. Global Oncolytic Virotherapy Market Size & Forecasts by Application 2022-2032
6.1. Segment Dashboard
6.2. Global Oncolytic Virotherapy Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Solid Tumors
6.2.2. Melanoma
Chapter 7. Global Oncolytic Virotherapy Market Size & Forecasts by End-User 2022-2032
7.1. Segment Dashboard
7.2. Global Oncolytic Virotherapy Market: End-User Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Cancer Research Institutes
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Amgen Inc
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. BioVex, Inc.
8.3.3. Circio Holding ASA
8.3.4. Daiichi Sankyo Company
8.3.5. DNAtrix
8.3.6. Lokon Pharma AB
8.3.7. Medigene AG
8.3.8. Oncolytics Biotech Inc.
8.3.9. PsiOxus Therapeutics
8.3.10. Shanghai Sunway Biotech Co., Ltd.
8.3.11. SillaJen, Inc.
8.3.12. Sorrento Therapeutics
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes